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Abstract
Synthetic lethality has been proposed as a way to leverage the genetic differences found in tumor cells to affect their
selective killing. Cohesins, which tether sister chromatids together until anaphase onset, are mutated in a variety of tumor
types. The elucidation of synthetic lethal interactions with cohesin mutants therefore identifies potential therapeutic
targets. We used a cross-species approach to identify robust negative genetic interactions with cohesin mutants. Utilizing
essential and non-essential mutant synthetic genetic arrays in Saccharomyces cerevisiae, we screened genome-wide for
genetic interactions with hypomorphic mutations in cohesin genes. A somatic cell proliferation assay in Caenorhabditis
elegans demonstrated that the majority of interactions were conserved. Analysis of the interactions found that cohesin
mutants require the function of genes that mediate replication fork progression. Conservation of these interactions
between replication fork mediators and cohesin in both yeast and C. elegans prompted us to test whether other replication
fork mediators not found in the yeast were required for viability in cohesin mutants. PARP1 has roles in the DNA damage
response but also in the restart of stalled replication forks. We found that a hypomorphic allele of the C. elegans SMC1
orthologue, him-1(e879), genetically interacted with mutations in the orthologues of PAR metabolism genes resulting in a
reduced brood size and somatic cell defects. We then demonstrated that this interaction is conserved in human cells by
showing that PARP inhibitors reduce the viability of cultured human cells depleted for cohesin components. This work
demonstrates that large-scale genetic interaction screening in yeast can identify clinically relevant genetic interactions and
suggests that PARP inhibitors, which are currently undergoing clinical trials as a treatment of homologous recombination-
deficient cancers, may be effective in treating cancers that harbor cohesin mutations.
Citation: McLellan JL, O’Neil NJ, Barrett I, Ferree E, van Pel DM, et al. (2012) Synthetic Lethality of Cohesins with PARPs and Replication Fork Mediators. PLoS
Genet 8(3): e1002574. doi:10.1371/journal.pgen.1002574
Editor: Douglas E. Koshland, University of California Berkeley, Howard Hughes Medical Institute, United States of America
Received November 2, 2011; Accepted January 16, 2012; Published March 8, 2012
Copyright:  2012 McLellan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: JLM was supported by a Frederick Banting and Charles Best Canada Graduate Scholarship from CIHR. PH is supported by the National Institutes of
Health (NIH; www.nih.gov/) and the Canadian Institutes for Health Research (CIHR; http://www.cihr-irsc.gc.ca/e/193.html). AMR is supported by the Canadian
Institutes for Health Research (CIHR; http://www.cihr-irsc.gc.ca/e/193.html) and the Natural Sciences and Engineering Research Council of Canada (NSERC; http://
www.nserc-crsng.gc.ca/ ndex_en ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hieter@msl.ubc.ca
. These authors contributed equally to this work.
Introduction
Defects in cohesin-associated genes are emerging as potential
drivers of tumor genomic instability and progression. Mutations in
cohesin genes have beenidentifiedin several tumor types (Reviewed
in [1]). Sequencing of over 200 human orthologs of yeast
chromosome instability (CIN) genes from 130 colon tumors found
that cohesin genes are mutated in 8% of tumor samples [2]. In a
recent study, Solomon et al. found the cohesin gene STAG2 mutated
in 21% of Ewing’s sarcomas and in 19% of both melanoma and
glioblastoma tumors [3]. Furthermore, altered cohesin gene
expression, either overexpression or underexpression is character-
istic of many tumors [4–7]. It has been shown that loss of cohesin
subunits induces genomic instability in human cancers and the
associated aneuploidy, as is observed in many cell lines with
mutations in cohesin, can itself lead to further genomic instability
[2,3,8]. These observations and the elevated mutational frequency
of cohesin in diverse tumor types suggest that cohesin dysfunction
may contribute to tumor development and progression.
Cohesins maintain sister chromatid cohesion and screens for
defects in sister chromatid cohesion have identified the core
cohesin complex, composed of Smc1, Smc3, Scc1 and Scc3, and
additional accessory and regulatory proteins [9]. Cohesins form a
ring structure that is thought to encircle sister chromatids and
physically tether them together until it is cleaved by separase
during anaphase [10,11]. Cohesin proteins contribute to DNA
repair and the regulation of gene expression in addition to
chromosome segregation (Reviewed in [12]). Although much is
known about the function of cohesin in regulating sister chromatid
cohesion and DNA damage repair, it is not as yet clear which
aspects of cohesin biology might contribute to tumor progression.
One approach to understanding the functional spectrum
associated with a gene of interest relies on the identification of
genetic interactions with other gene mutations. Negative genetic
interactions occur when the double mutant shows a synthetic
growth defect manifested as severe slow growth or lethality
(synthetic sickness/lethality) when compared to both single
mutants. Synthetic sick or lethal interactions with genes mutated
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i gin cancer can identify potential therapeutic targets [13,14]. A
clinically relevant example of a synthetic lethal (SL) genetic
interaction is the SL interaction between mutations in breast
cancer susceptibility genes BRCA1 or BRCA2 and loss of function
of the Poly-ADP Ribose Polymerases (PARP). Two groups found
that BRCA1- and BRCA2-defective cells are sensitive to knockdown
of PARP or chemical inhibition of PARP activity [15,16]. This has
lead to the development of PARP inhibitors as chemotherapeutics.
PARP inhibitors are being evaluated in Phase II clinical trials for
use in homologous recombination (HR) deficient breast and
ovarian tumors [17–20].
In addition to identifying synthetic lethal interactions that could
represent potential drug targets, comprehensive genetic interaction
networks can also lead to new functional insights [21]. Mapping
global genetic interactions in human cells is feasible but techniques
lag behind those currently available in budding yeast. Synthetic
genetic array (SGA) is a large-scale genetic interaction screening
approach in yeast that facilitates the collection and analysis of
positive and negative genetic interaction data [22–24]. The use of
yeast as a model organism to identify conserved genetic
interactions with potential cancer therapeutic value has proven
effective [14]. The inclusion of the metazoan animal model, C.
elegans, in the genetic interaction testing pipeline can also
contribute new insights as nematodes have a gene complement
more akin to humans and contain several cancer-relevant genes
not found in yeast, such as BRCA1, BRCA2, TP53 and the family of
poly(ADP)-ribose polymerases (PARPs) [25–28]. Furthermore, C.
elegans mutants and double mutants also present informative
phenotypes, such as apoptotic defects, cell cycle checkpoint
dysfunction, and chromosome loss, in the context of a multicellular
animal model, which can lead to a better understanding of the
biological processes affected by specific genetic interactions [29].
The large number of genetic interactions that can be identified by
comprehensive genetic interaction screens such as SGA can
identify key processes or pathways that when disrupted result in
synthetic lethality. These pathways could be targeted for SL
therapeutic intervention even if the specific genes are not well
conserved from the yeast to humans.
In this study, we performed digenic SGA screens in S. cerevisiae
using three hypomorphic cohesin mutations to identify common
processes required for survival when cohesin is mutated.
Interactions were tested for conservation in C. elegans using an
assay for defects in somatic cell proliferation [30]. We found that
proteins mediating replication fork progression and stability are
required in cohesin mutants of both S. cerevisiae and C. elegans.
Based on these findings we predicted that other mediators of
replication fork stability not conserved in yeast, such as PARP,
would be required for viability in higher eukaryotic cells with
mutations in cohesin. To test this prediction, we expanded the
screen in C. elegans to include PAR metabolism (pme) mutations and
found that pme mutants genetically interact with him-1/SMC1 in C.
elegans. We found that this genetic interaction was conserved in
cultured human cells and small molecule PARP inhibitors,
currently being evaluated in clinical trials, were effective in
inhibiting growth in cohesin depleted cultured human cells.
Beginning with systematic screens in a simple model eukaryote this
study identifies conserved and clinically relevant genetic interac-
tions between cohesin and replication fork modulators including
the chemotherapeutic target PARP.
Results
Systematic quantitative analysis of cohesin genetic
interactions
Synthetic genetic array (SGA) technology was used to screen
temperature sensitive (ts) alleles of two cohesin components (smc1-
259, scc1-73) and one cohesin loader (scc2-4) against ,95% of
genes in S. cerevisiae as represented by non-essential gene deletions
[31], ts [32] or decreased abundance by mRNA perturbation
(DAmP) [33] alleles. All three cohesin alleles have mutations in
similar regions as those identified in colon tumors (SMC1, SCC2)o r
in the Catalogue of Somatic Mutations in Cancer (COSMIC)
(SCC1) (Table 1, Figure S1).
The interaction data was sequentially filtered using several
criteria to increase quality and focus. Only negative genetic
interactions with a p-value less than 0.05 and a large interaction
magnitude (E-C value less than 20.3, see Methods) were
considered. Filtering based on magnitude enriched for interactions
that cause a severe fitness defect when compared to the single
mutant. To reduce false positives and increase the potential of
identifying drug targets that interact with mutations in multiple
cohesin subunits, we eliminated genes that interacted with only a
single cohesin query gene, leaving 55 genes (Figure S2). Finally, to
focus on interactions that may have relevance to the biology of
cohesins and cancer, we eliminated genes that did not have an
obvious human homolog (see Figure 1A, Table S1). Using these
criteria, 39 of 55 genes (71%), defining 90 putative negative
genetic interactions, had an identifiable homolog in humans
(Table S1). Six genes were removed from further analysis for
technical reasons, leaving 33 genes comprising 78 genetic
interactions.
To validate this subset of interactions identified in the primary
screen, 99 double heterozygous diploids (33 genetic interaction
genes by 3 cohesin query genes) were reconstructed, the specific
gene deletions confirmed by DNA analysis, and double mutant
phenotypes retested by random spore analysis. To assess whether
growth defects were greater than additive, growth curve analysis
was performed on all viable double mutants (Figure 1B; Figures
S3, S4, S5, S6, S7; Tables S2, S3, S4). Random spore and growth
curve analyses achieved several goals; 1) Reduced the false positive
rate by removing genes with an incorrect well address in the high
throughput arrays (8% of hits), 2) Eliminated condition artifacts by
Author Summary
Synthetic lethality has been proposed as a way to leverage
the genetic differences found in tumor cells to affect their
selective killing. Many tumor types contain mutations in
the cohesin genes. Identifying synthetic lethal genetic
interactions with cohesin mutations therefore identifies
potential therapeutic targets for these tumors. We have
used the simple model organisms yeast and C. elegans to
screen for synthetic lethal genetic interactions with
cohesin mutations. We found that cohesin mutants require
the function of proteins that regulate the replication fork
for viability. In human cells, Poly-ADP Ribose Polymerases
(PARPs) have been shown to repair stalled replication forks
and are the target of a class of anti-tumor chemothera-
peutics called PARP inhibitors. Based on our finding that
cohesin mutants required replication fork regulators and
the role of PARP at the replication fork, we tested the
effect of PARP inhibitors in human cells with reduced
cohesin. We found that PARP inhibitors reduced the
viability of cohesin-depleted cells suggesting that PARP
inhibitors may be effective for the treatment of tumors
containing cohesin mutations. Together our data demon-
strate the utility of comprehensive interaction screens in
simple organisms to identify clinically relevant genetic
interactions.
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same drug selective conditions as SGA (random spore) and in rich
medium (growth curve), 3) Yielded an additional quantitative
measure of each synthetic sick interaction, and 4) Identified
additional true positives not identified under SGA conditions.
During subsequent testing 4 out of 78 (5%) interactions
identified by SGA did not result in a negative genetic interaction
and an additional 20 interactions not observed by SGA were
identified for a total of 94 negative genetic interactions with the
three cohesin query genes (Figure 1C). 29 (31%) of these
interactions involve essential genes, highlighting the importance
of screening against essential gene collections.
Negative genetic interactions with cohesin are conserved
in C. elegans
One of our goals is to identify interactions that are conserved in
mammalian cells and thus relevant to the development of
therapeutics. We hypothesized that interactions that are conserved
among eukaryotes are more likely to be conserved in higher
animals and therefore we tested the validated S. cerevisiae
interactions in the model metazoan, C. elegans. We used a visual
screen that monitors defects in development of the C. elegans vulva
to identify synthetic genetic interactions that resulted in defects in
somatic cell proliferation [30]. These vulval cell divisions occur
late in nematode development [34], so perturbations do not affect
organismal viability, which allows us to screen for interactions
using gene mutations or RNA interference (RNAi) knockdowns
that are potentially embryonic lethal. We tested the C. elegans
homolog of all genes that had a verified genetic interaction with
one of the cohesin genes in S. cerevisiae and for which there was an
RNAi construct available (Table S1). Cohesins are essential genes,
so we used a viable hypomorphic mutation in the C. elegans SMC1
ortholog, him-1(e879), and treated these worms with RNAi by
feeding. Adult worms were bleached to obtain embryos that
hatched into onto plates seeded with bacteria expressing different
dsRNA constructs. When the embryos hatch into L1 larva they eat
the dsRNA-expressing bacteria, which initiates systemic RNAi
knockdown. An increased frequency of defects in the mutant
treated with RNAi, compared to the predicted additive effect for
the mutant and RNAi separately, is indicative of a genetic
interaction. We observed a clear increase over the predicted
additive frequency of Pvl in 23/28 (82%) interactions tested
(Figure 2) demonstrating that most interactions are conserved
between S. cerevisiae and C. elegans.
Analysis of cohesin network sub-groups
Each gene in the network was assigned to one of several broad
functional groups based on gene descriptions reported in the
Saccharomyces Genome Database (SGD). These groups were the
spindle, microtubules and kinetochore (39%), mRNA processing
(12%), replication factors (24%), and a group that contains genes
involved in general cell metabolism (24%).
One hypothesis for a genetic interaction is that two mutations
that cause the same phenotype, when combined cause a
cumulative phenotype that breaches the tolerance level of the
cell. One phenotype of cohesin mutants is increased CIN and we
therefore investigated whether the interactors also cause CIN
when mutated. For this analysis we used information collected
from SGD and a recently performed screen for CIN in essential
genes [35] (Table S5). We found most of the genes, except those in
the metabolism group, cause CIN as measured by a variety of
assays such as chromosome transmission fidelity (CTF) and gross
chromosomal rearrangements (GCR) in yeast [35].
Cohesin mutations are synthetic lethal with mutations in
replication fork mediators
To probe the identified interactions further, we profiled the
interactions based on strength by filtering the network to include
only SL interactions. We hypothesized that these interactions
would indicate the most critical processes when cohesin genes are
disrupted (Figure 3A). This analysis revealed five genes specifically
involved in replication fork progression and stability that were SL
with all three cohesin alleles tested. Ctf8p and Dcc1p are
components of the alternative replication factor C Ctf18 clamp
loader (altRFC
CTF18) that controls the speed and restart activity of
the replication fork [36]. Rad61p acts with Pds5p to bind cohesin
and regulates its association with chromatin [37,38]. Chl1p is a
DNA helicase that interacts with CTF18 and physically with
Eco1p [39]. Ctf4p (human AND1) has a role in coupling the
Mmc2-7p helicase replication progression complex to DNA
polymerase a [40]. Csm3p functions in a complex with Tof1p
and Mrc1p to control stable pausing of the replication fork
[41,42]. We collectively call these genes replication fork mediators.
The SL interaction of replication fork mediators with multiple
Table 1. Mutations in cohesin genes seen in tumors.
Human Gene
(Yeast Gene) Mutations reported in CIN colon tumors Cancer mutations reported in COSMIC*; cancer type
SMC1L1 (SMC1) F369L (1186C.T)
R434W (1300C.T)
I560M (1680 C.G)
I1186V (3556G.A)
CSPG6 (SMC3) R879X (2635C.T) A44V (131C.T); CNS
RAD21 (SCC1) Q474stop (1420C.T); lung
E498K (1492G.A); skin
STAG3 (SCC3) I795T (24117T.C) F660L (1980C.A); lung
NIPBL (SCC2) R479STOP (1435C.T)
Frameshift after aa 992
Q554STOP (1660C.T)
M1793K (5378T.A)
E1674K (4939G.A); breast
S349C (1045A.T); lung
Deletion, Frameshift after aa 2241; lung
*Silent mutations not reported in this table. Amino acid: aa.
doi:10.1371/journal.pgen.1002574.t001
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perturbations of the replication fork.
To investigate the biology underlying the interaction between
cohesin and replication fork mediator mutations the frequency of
apoptosis in the C. elegans germline was analyzed. In the C. elegans
germ line, nuclei with DNA damage are removed by apoptosis and
increased germline apoptosis can be indicative of increased DNA
damage [43]. Apoptosis levels were quantified in the germline of
the him-1(e879) mutant and were found to be elevated above that
of wild type (Figure S8). When him-1 mutant animals were treated
with RNAi against csm-3, rad-61, ctf-8, ctf-4 and dcc-1 an increase in
apoptosis was detected. Apoptotic bodies in these cases were
typically found in large clusters, rather than being distributed
throughout the pachytene region, reminiscent of irradiated
animals (Figure S8). These results suggested that the defects in
both HIM-1 and replication fork mediator function leads to DNA
damage that results in increased apoptosis.
We have shown that cohesin mutations are synthetic lethal with
mutations in genes that mediate replication fork progression
(Figure 1, Figure 2, Figure S8) but are not synthetic lethal with any
DNA repair mutants (Table S6). These results suggest that the
cohesin mutations lead to replication fork progression defects but
not directly to DNA damage. This is further supported by the
observation that the yeast cohesin mutations do not result in
Rad52p foci accumulation, which are indicative of HR repair
intermediates [44]. Additionally, elimination of the HR repair
pathway by deletion of RAD51 in replication fork mediator-
cohesin double mutants did not rescue lethality, suggesting that
toxic recombination intermediates are not the cause for lethality in
a cohesin mutant background (Figure S9). These data suggest that
Figure 1. S. cerevisiae cohesin genetic interaction network. A) Venn diagrams depicting how SGA data was filtered. i. Interactions that had a
negative interaction value and were statistically significant (p-value,0.05). ii. Interactions that had a relatively weak interaction score (Experimental
value – Control value.2.3) were eliminated to enrich for biologically significant interactions. iii. Genes were eliminated if they failed to interact with
$2 of the cohesin query genes and if they did not have a human homolog (Table S3). iv. Summary of the final network after random spore and
growth curve retesting and validation. The total number of interactions in a given Venn diagram is underlined. The total number of genes is shown in
red. The numbers in brackets indicate interacting genes remaining after removal of 6 genes for technical reasons. B) Representative subset of growth
curve data. The T-stat, which takes into account the interaction magnitude and statistical significance, is shown in blue. All growth curve data can be
found in Figures S3, S4, S5, S6 and Tables S1, S2, S3. C) Expanded view of the final network summarized in A iv. Red lines indicate SL interactions and
black lines represent SS interactions. The black line thickness represents interaction strength.
doi:10.1371/journal.pgen.1002574.g001
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intimately tied to the regulation of replication progression and led
us to further investigate this relationship.
him-1 genetically interacts with the PARP pathway in C.
elegans
The finding that replication fork mediator mutations are
synthetic lethal with hypomorphic mutations in cohesin led us to
hypothesize that inhibitors of replication fork stability could result
in specific killing of tumors containing cohesin mutations. At
present there are no small molecule inhibitors of the replication
fork mediators identified in our SGA screen. However, in higher
eukaryotes there are additional factors that protect and regulate
the replication fork. An early mediator of replication fork stability
is the family of Poly (ADP-ribose) polymerases (PARPs). PARPs
have been shown to localize to stalled forks and mediate restart
[45]. Furthermore, there are effective small molecule inhibitors of
PARP and although PARPs are not present in yeast they are
present in C. elegans. To assess whether PARP metabolism plays a
role in maintaining viability in a cohesin mutant, we made double
mutants with him-1(e879) and the five PAR metabolism enzyme
(pme) genes in C. elegans. pme-1 and pme-2 are the C. elegans orthologs
of PARP1 and PARP2, respectively [28]. pme-3 and pme-4 are
homologs of Poly (ADP-ribose) glycohydrolase (PARG), which
depolymerizes ADP-ribose polymers into monomeric ADP-ribose
units [46]. pme-5 is the C. elegans ortholog of PARP5, which is also
known as TANKYRASE [47]. All him-1; pme double mutants exhibit
decreased brood sizes and an increase in the frequency of arrested
embryos, suggesting that him-1 interacts with all identified
members of the PAR metabolism family in C. elegans (Figure 3B).
Strikingly, him-1; pme-2(ok344) double mutants had a very high
frequency of protruding vulva phenotype (Figure 3C) indicative of
somatic cell proliferation defects.
PARP inhibition reduces the viability of SMC1 depleted
HCT116 cells
The strong negative genetic interactions in C. elegans between a
hypomorphic cohesin mutation and the pme mutations prompted
us to test whether this interaction is conserved in human cells using
the colon cancer-derived, near diploid cell line, HCT116 [48]. We
used an early generation PARP inhibitor, benzamide [49], to
inhibit PARP function in a panel of HCT116 cells treated
individually with siRNA against several cohesin genes (SMC1,
SMC3, SCC2/NIPBL, SCC1/RAD21, SCC3/STAG1 and SCC3/
STAG3). High content digital imaging microscopy (HC-DIM) was
used to count Hoescht stained nuclei. Although HC-DIM is not
necessary to count nuclei it allows more nuclei to be counted and
more technical replicates to be performed in a timely manner.
This preliminary assay suggested that HCT116 cells depleted of
cohesin were sensitive to PARP inhibition (Figure S10). We further
investigated this interaction using a more specific, third generation
PARP inhibitor, olaparib, which has been evaluated in phase II
clinical trials in the treatment of HR deficient breast and ovarian
cancers [17,19,20]. BRCA1 siRNA treated cells were used as a
Figure 2. C. elegans genetic interactions. Graph depicting the frequency of worms with a protruding vulva (Pvl) when VC2010 (WT) and SMC1/
him-1(e879) strains are treated with various RNAi constructs. The RNAis tested targeted the C. elegans homologs of genes that interact with one of the
cohesin query genes in the S. cerevisiae validated network (Figure 1C). Homologs with associated e-value BLAST scores can be found in Table S1.
Interactions are ranked by the difference between the frequency of Pvl in VC2010 and him-1 strains. The predicted value is the sum of both the him-1
and N2 background Pvl frequencies and the effect of the RNAi on WT. unc-22 and 6 randomly chosen RNAi clones from chromosome 1 are included
as negative controls. Error bars represent SEM.
doi:10.1371/journal.pgen.1002574.g002
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highly sensitive to PARP inhibitors [15,16]. Accordingly, we found
BRCA1 siRNA treated cells were very sensitive to olaparib
(Figure 4). We also found by visual inspection that SMC1 siRNA
treated cells exhibited reduced cell proliferation in response to a
range of olaparib concentrations using a 24 well plate survival
assay whereas untreated and GAPDH siRNA treated cells
appeared only mildly affected (Figure 4A). We quantified the
specific sensitivity using an expanded 10 cm dish survival assay
where cells treated with siRNAs were continuously exposed to
0.6 mM olaparib and colonies were stained and counted after a 10
day period (Figure 4B, 4C, 4E). We also saw evidence that
HCT116 SMC1 knockdown cells exposed to olaparib exhibited
proliferation defects using HC-DIM. Overall, we observed a
significant dose dependent decrease in cell number in the BRCA1
and SMC1 treated cells as compared to GAPDH (Figure 4D).
PARP inhibition reduces viability in HTB-38, a human cell
line with low parylation levels
We were concerned that the effect of PARP inhibition was
complicated by the fact that HCT116 cells have a high level of
endogenous PARP activity due to deficiencies in mismatch repair
(MMR) [50,51]. Consistent with previous reports, we observed
relatively high PAR levels, which are indicative of PARP activity,
in untreated HCT116 cells (Figure 5A). We also found that
HCT116 cells treated with 0.6 mM olaparib showed a 54%
Figure 3. Sub-optimal cohesin requires replication fork mediators. A) The validated S. cerevisiae cohesion network was filtered to include
only SL interactions. Gene nodes are colored according to the legend in Figure 1C. B) Brood size (total number of eggs laid), embryonic lethality, and
percentage of male progeny and C) Frequency of Pvl in the indicated single and double mutants. Error bars represent SEM.
doi:10.1371/journal.pgen.1002574.g003
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rule out the confounding effects of elevated PAR in the HCT116
cell line, we repeated the colony forming assay, with and without
olaparib treatment, on a second colon cancer-derived cell line that
was MMR-proficient, HTB-38. First, we confirmed that, as
previously reported, HTB-38 cell lines did not exhibit increased
PAR levels (Figure 5A). We found that GAPDH and untransfected
HTB-38 cells were insensitive to olaparib (Figure 5B, 5C) unlike
the HCT116 cells that showed mild sensitivity to olaparib
(Figure 4B). However, olaparib treatment decreased viability in
the HTB-38 cells treated with siRNA targeting either BRCA1 or
SMC1, confirming the sensitivity to PARP inhibitors of SMC1-
depleted cells. To determine whether the sensitivity to PARP
inhibition was limited to SMC1 or was more general, extending to
defects in other cohesin components, we treated cells with siRNA
targeting the cohesin components SMC3 or RAD21/SCC1.W e
observed growth defects of similar strengths among all cohesin
subunits tested. These experiments demonstrate that cells with
cohesin defects are sensitive to PARP inhibition.
Discussion
Cohesin dysfunction appears to have a significant role in the
formation and progression of tumors (Reviewed in [1]). Here we
show that replication fork stability genes are required for viability
in cohesin mutants across species. Using data from yeast SGA
analyses we were able to predict synthetic lethal interactions in
human cells between cohesin mutations and PARP inhibitors,
even though PARP is not present in yeast, demonstrating the
power of large-scale genetic interaction screens for synthetic
lethality with genes mutated in tumors.
Figure 4. SMC1 siRNA treated human cells are sensitive to the PARP inhibitor olaparib. All experiments were performed with HCT116, a
near diploid, colon cancer derived cell line that is MMR deficient. In all panels HCT116 cells are treated with siRNA targeting GAPDH, BRCA1 or SMC1 or
untreated (in indicated). A) 24 well plate clonagenic survival assay with HCT116 siRNA treated cells exposed to olaparib concentrations up to 1.5 mM.
B) 10 cm dish clonagenic survival assay looking at the number of colonies after 10 days in the presence of 0.6 mM olaparib. C) Normalized colony
numbers from the clonagenic assay. D) HC-DIM counting Hoescht positive nuclei of siRNA treated cells after 3 days of olaparib exposure. E) Western
blot of samples collected from the 10 cm survival assay (B). Error bars represent SEM.
doi:10.1371/journal.pgen.1002574.g004
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SL interactions in model organisms can identify candidate genes
or pathways that can be targeted for inhibition leading to specific
killing of tumor cells with specific mutations [13]. We used SGA
technology in yeast to generate a network of negative genetic
interactions, using hypomorphic mutations in cohesin as query
genes, with the aim of elucidating the genetic pathways needed for
survival when cohesin function is compromised. By overlaying the
results from three separate SGA screens, using two cohesin core
components (SMC1 and SCC1) and one cohesin loader (SCC2)a s
queries, we identified common interactions with compromised
cohesin rather than those that were allele or component-specific.
While the screens found scores of single negative interactions with
each of the three query mutants (Figure 1A), the goal of this study
was to identify interactions that are more likely to be SL with the
wide-range of cohesin-associated mutations observed in human
tumors. Negative genetic interactions specific to only one of the
three cohesin mutants may reveal specific aspects of cohesin
components and these interactions warrant further investigation.
The filtered S. cerevisiae interaction set identifies many processes
that would be predicted to interact with cohesin dysfunction. For
example, mutations affecting the mitotic spindle, kinetochore and
microtubules, including prefoldin, were found to result in synthetic
growth defects with at least two of the three query mutants. Given
the role of cohesin in regulating chromosome segregation leading
to the anaphase transition [9], mutations affecting the spindle or
kinetochore would be predicted to interact with cohesin mutations.
Other interactions that do not appear to be related to cohesin
Figure 5. SMC1 and PARP genetically interact in HTB-38 human cells. All experiments were performed with HTB-38, a near triploid colon
cancer derived cell line that is MMR proficient. A) Western blot stained with anti-PAR. BV80 is MLH12/2 and is the matched line to BV79 which is
MLH1+/2. RPE-1 was used as a control cell line for measuring PAR levels. RPE-1 is an hTERT immortalized retina epithelial cell line. B) Normalized
colony numbers for HTB-38 cells treated with the indicated siRNA and exposed to 0.6 mM olaparib. C) Raw colony numbers for the clonagenic assay
shown in B. Error bars represent SEM.
doi:10.1371/journal.pgen.1002574.g005
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example ten interactions were identified with components of
mRNA processing and the translation machinery. In these cases,
further work will be needed to ascertain whether this is a general
synergistic effect on viability or whether the interaction results in a
specific defect.
When interactions were filtered based on strength, keeping only
those interactions that were SL, the predominant genes were those
involved in mediating replication fork progression. These included
two of the three genes in the alternative RFC
CTF18, the replisome
components CSM3 and CTF4, the replication and cohesion-
associated helicase CHL1, and the cohesin regulator RAD61. All of
these interactors are known to mediate replication fork stability
and progression [36–42,52–54]. Furthermore, mutations affecting
these genes also result in chromosome cohesion defects [55],
thereby linking replication fork stability and sister chromatid
cohesion. The SL interactions are not specific to mutations that
accelerate or impair replication fork progression. In fact, the Alt-
RFC
CTF18, which promotes replication fork progression, does so
by regulating the acetylation of Smc3p [36], which in turn inhibits
the association of Smc3p and Rad61p [52,53]. In contrast to the
Alt-RFC
CTF18, Rad61p binding to Smc3p slows replication fork
progression [36]. Rad61p is known to destabilize the association
between cohesin and chromosomes [38]. The requirement for
RAD61 in the cohesin mutants is particularly interesting given the
correlation of elevated expression of the human RAD61 ortholog,
WAPL, with certain cancers. Its importance in maintaining the
viability of tumor cells was demonstrated by the fact that
knockdown of WAPL in cervical cancer cell lines resulted in cell
death [4]. Similarly, we observe synthetic lethality when we
knockout RAD61 in the cohesin mutants, thereby demonstrating
that Rad61p function is needed when cohesin function is
compromised.
The synthetic lethality of the cohesin mutations with replication
fork mediator mutations suggested that the replisome must be
stabilized when cohesin is mutated to ensure proper progression.
Interestingly, cohesin mutants did not show negative genetic
interactions with DNA repair genes such as the RAD52-
complementation group of HR genes, the RecQ helicase SGS1,
or the structure-specific endonuclease MUS81. In addition, the
cohesin mutants do not accumulate Rad52p foci [44], which is
indicative of increased DNA damage or DNA repair intermedi-
ates. These data suggested that cohesin mutations on their own do
not lead to DNA double strand breaks or fork collapse, both of
which require HR for resolution. Cohesin dysfunction may impact
replication fork dynamics, but these events are tolerable in the
presence of fork stabilizing proteins. Cohesin may also have a role
in modulating fork progression. As vertebrate replicons span
between approximately 60 and 140 kb [56,57] and cohesin is
associated, on average, with DNA every 10–20 kb [58–61], each
fork must theoretically pass several cohesin complexes [36]. One
mechanism to prevent fork collapse is to minimize the distance
between the leading strand helicase and the polymerase. If the
polymerase stalls and the helicase continues to advance, single
stranded DNA is exposed and the fork becomes more fragile.
Rad61p association with cohesin is thought to induce a closed
cohesin conformation that limits fork progression [36]. When the
cohesin ring changes to a more restrictive conformation it may
prevent helicase and polymerase separation. Support for cohesin
moderating fork progression comes from the finding that human
SMC1 is phosphorylated by ATR in response to S phase stress
[62] and that this modification is required for activation of the
replication checkpoint.
PARP inhibition reduces the viability of cohesin-depleted
cells
In higher eukaryotes, additional factors regulate replication fork
stability and progression, one example being the family of
poly(ADP-ribose) polymerases (PARPs). PARPs play a major role
in DNA metabolism including aspects of repair and replication
(reviewed in [63]). PARP was recently found to be activated by
stalled replication forks and promoted replication fork restart [45].
We found that loss of PARP and PARG orthologs synergized with
a mutation in him-1/SMC1 in C. elegans resulting in a decrease in
cell and organismal viability. In human cells, depletion of SMC1,
SMC3 or SCC1 by siRNA caused sensitivity to the PARP-inhibitor
olaparib. Interestingly, this sensitivity was comparable to that
observed when we depleted BRCA1 by siRNA and then treated
cells with olaparib. The interaction between multiple cohesin
subunits and PARP was found to be cell line independent,
suggesting a robust interaction. Recent emerging hypotheses have
proposed alternate fork restart pathways where one branch is HR
mediated and the other requires PARP [63]. It has been suggested
that BRCA1/2 are synthetic lethal with PARP1/2 because of an
inability to restart stalled or collapsed forks. This hypothesis is
interesting given the connection we observe between cohesin and
fork progression mediators.
Given our findings regarding the importance of replication fork
mediators in the presence of cohesin mutations, it is possible that
PARP activity is needed for replication fork stability or lesion
bypass in the cohesin mutants or knockdown cell lines. However,
while synthetic lethal interactions between cohesin mutations and
replication fork mediators led to testing PARP inhibitors, the
mechanism of the PARP-cohesin interaction is not known because
PARP and cohesin each have multiple functions that could be co-
dependent. For example, it is possible that the synthetic lethality of
cohesin knockdown with PARP inhibition is related to the role of
cohesin in HR [64] PARP inhibition is known to be effective in
killing cells with defective HR, such as BRCA1, BRCA2 and ATM-
deficient cells [15,16]. It is possible that the synthetic lethality of
cohesin knockdown and PARP inhibition is due to either or both
mechanisms. Although further investigation is needed to identify
the specific mechanism of lethality, our data indicate PARP
inhibition is a potential treatment for tumors with cohesin or
cohesin-related mutations, which represent a significant propor-
tion of colorectal, ovarian, breast and other tumors [1–3].
Materials and Methods
S. cerevisiae strain construction and SGA screens
Temperature sensitive (ts) cohesin alleles were marked with
URA3 as described previously [65,66] and were used as query
genes in SGA screens. Query genes were screened against the non-
essential deletion collection [31] and a collection of DAmP [33]
and ts [32] alleles representing essential genes. SGA screens were
performed in biological triplicate, each with three technical
replicates using a Singer RoToR essentially as described [67].
SCC1 and SCC2 were screened at 30uC while SMC1 was screened
at 25uC due to slow growth at higher temperatures. See Tables S7
and S8 for a full list of S. cerevisiae strains used in this study.
Double mutant reconstruction and random spore
analysis
Double heterozygous mutants were recreated by mating each of
the single mutants and selecting on 2ura, +G418 plates. The
cohesin mutant parent strains were the same query genes used for
SGA screens and the other parent was pulled directly from the
array plates. Heterozygotes were confirmed by PCR analysis to
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to the upstream and downstream sequences of each gene locus
assayed, were used in PCR reactions in most cases. Random spore
was performed at 25uC as previously described [30]. Tetrad
analysis would have been a true independent measure of a genetic
interaction but the cohesin mutants, singly, exhibit relatively high
rates of random spore death, making tetrad analysis infeasible on
this scale. Briefly, spores were plated onto haploid selection plates
containing canavanine and thialysine. Single selection plates were
additionally either 2ura or +G418. Double mutants that did not
grow on the double selection plates (2ura, +G418) were
considered SL. Several isolates of viable double mutants were
isolated from random spore analysis for growth curve analysis.
S. cerevisiae growth curves
All viable double mutants were analyzed by growth curve
analysis as previously described [30] with slight modifications.
Briefly, strains were grown overnight in YPD, diluted to an optical
density600 nm (OD) of 0.2 and incubated for 4 hours at 25uC.
Strains were then diluted to an OD of 0.3 and 100 ul was added to
each well of a 96 well plate. 100 ul of fresh YPD was added to
each well for a final OD of 0.15. For each plate, fifteen replicates
were performed for wild type (WT), while three replicates were
performed for each of the other strains analyzed. OD readings
were made every 30 min, after 3 min of shaking, over a period of
24 hrs at 26uC (5 plates) or 30uC (6 plates) on a Tecan M1000.
Growth curves for each strain can be found in Figure S3.
Growth curve analysis
Strain fitness was defined as the logarithm of the area under the
curve (AUC) and was calculated using Simpson’s rule in R [68].
Separate, parallel analyses were performed for plates grown at
26uC and 30uC. Measurements were normalized for plate effects
such that the average estimated strain fitness for the wild type
curves was constant across each set. Interaction effects were
assessed with a linear model of the form:
Fq,g~Fwtztqztgztq,g
Fq,g is the fitness for a double-knockout of query gene q and non-
essential gene g, Fwt is the fitness for the wild type growth curves,
tq is the single-knockout effect for each of the three query genes
(scc1-73, smc1-259, scc2-4), tg is the single-knockout effect for each
of the other non-essential genes assessed, and tq,g is the double-
knockout interaction effect associated with genes q and g. Under
additive neutrality, non-interacting gene pairs will have an
interaction term tq,g of zero:
Fneut
q,g ~Fwtztqztg tq,g~0

Values of tq,gv0 indicate SS interactions, while values of tq,gw0
indicate alleviating interactions. After fitting this model, the
significance of the estimated interaction effects tq,g was assessed.
See Text S1 and Tables S2, S3, S4 and Figures S4, S5, S6, S7 for
additional details and statistical analysis.
Homolog identification
Homology was determined using protein BLAST to query the S.
cerevisiae protein sequence against the non-redundant protein
sequences database using default parameters. S. cerevisiae ORF
translation sequences were obtained from the Saccharomyces
Genome Database (SGD) and Homo sapiens (taxid:9606) and
Caenorhabditis elegans (taxid:6239) organisms were queried for
sequence matches. The algorithm used was blastp (protein-protein
BLAST) and all other parameters were set as default settings.
Homology was considered to exist if an identified match had an
expect value less than 1e-05. In cases where no homologous match
was identified in either C. elegans or H. sapiens, ‘No human, C. elegans
match’ was entered into Table S1. In some cases, such as with the
S. cerevisiae gene DCC1, no direct C. elegans sequence match could
be found. However, if the identified H. sapiens protein sequence
match was used as a BLAST query against the C. elegans database a
match, K09H9.2, could be obtained. In analogous situations, such
as with the S. cerevisiae gene MDM20, the C. elegans sequence
obtained through BLASTp was used to query the human database
for homologous sequences. In these cases if the identified match
had an expect value greater than 1e-05 the literature was
consulted to determine whether the identified protein was
considered homologous by other independent groups. An example
where the literature was consulted was to identify the human
homolog of S. cerevisiae RAD61, WPL-1.
C. elegans genetic interactions and SYTO12 staining
The Pvl somatic cell proliferation assay was performed as
previously described [30]. SYTO12 staining was performed on
young adult worms that had been pre-treated with RNAi by
feeding by bleaching gravid adults onto RNAi plates. Worms were
incubated in the dark with 33 mM SYTO12 in M9 buffer for 3 hrs
and then destained for 1 hour on fresh RNAi plates. Images were
captured immediately after destaining on a Zeiss Axioplan 2
microscope using a 406lens.
C. elegans double mutant strain construction and brood
analysis
See Table S9 for strains used. him-1(e879) males were mated to
either pme-1(ok988), pme-2(ok344), pme-2(tm3401), pme-3(gk120),
pme-4(ok980) or pme-5(ok446) hermaphrodites. Homozygous him-1
mutants were followed by the high frequency of males (,10%) and
all other mutations were followed by PCR. pme-1 him-1 animals
were balanced by hT2 and homozygous him-1; pme-2(ok344)
animals were balanced by mIn1.
Cell culture and siRNA
Cells were cultured as previously described [14]. siRNAs and
transfection reagents were purchased from Dharmacon. For
siRNA transfection experiments 300,000 and 550,000 cells were
seeded into 6-well dishes for HCT116 and HTB-38 cell lines,
respectively. Transfection occurred 24 hours after seeding using
ON-TARGETplus 25 nM siRNA pools. Transfection reagent was
removed 12 hours post-transfection and following an additional 6–
8 hours of recovery cells were transferred to fresh culture dishes
and allowed to expand for 3–10 days, depending on the assay. For
the clonogenic survival assays 1000 and 500 cells were seeded per
well in 24 well dishes and 10 cm plates, respectively. Cells were
allowed to attach for 10 hours and then olaparib was added at the
indicated concentration. Cells were fixed with 4% paraformalde-
hyde (PFA) in phosphate buffered saline (PBS) and stained using
0.1% crystal violet in 95% ethanol after 7 and 10 days for the 24
well plate and 10 cm dishes, respectively for HCT116. HTB-38
cells are slower growing and were stained with crystal violet at day
12. Drug exposure was continuous during this time and the 10 cm
dishes were supplemented with fresh media containing 0.6 mM
olaparib at day 5. High content digital imaging microscopy (HC-
DIM) assays were performed by plating 1000 cells per well in 96
well plates. Cells were allowed to settle for 10 hours and then
either benzamide or olaparib was added at the indicated
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exposure and stained with Hoescht dye #33258 (Molecular
Probes). Plates were subjected to HC-DIM using a Cellomics
ArrayScan with a 206(81 images/well) or 106(16 images/well)
dry lens. The total number of Hoescht-positive nuclei was
determined using a Cellomics Target Activation algorithm and
normalized to each siRNA treatment (GAPDH, BRCA1 or SMC1).
Western blots were performed on protein extracts collected from
asynchronous, sub-confluent cells harvested 3 days post-transfec-
tion as detailed previously [2]. Olaparib was purchased from
Selleck and Benzamide was purchased from Aldrich. Antibodies
were purchased from Millipore (BRCA1 07-434), Abcam (SMC1
ab9262, alpha Tubulin ab56476) and Trevigen (PAR 4336-BPC-
100). HTB-38 and RPE-1 cells were purchased from ATCC and
BV79 and BV80 were kindly provided by B. Vogelstein.
Supporting Information
Figure S1 Cohesin mutations found in colon tumors. Compar-
ison of SMC1 orthologs in H. sapiens, C. elegans, and S. cerevisiae.
Mutations identified in colon tumors are indicated on the human
gene and protein domains are shown on the S. cerevisiae gene. The
number of amino acids (aa) are shown on the right hand side. B)
SCC2 mutations. C) SCC1 mutations. D) Schematic of cohesin and
loaders (adapted from [12]).
(TIF)
Figure S2 SGA network. Negative genetic interactions from
three screens were overlaid to find common interactions. Green
circles indicate genes conserved in humans and purple circles
represent genes with no identifiable sequence orthologs. Circles
outlined in black represent essential S. cerevisiae genes. 55 genes, not
including the cohesin query genes, are represented in this figure.
(TIF)
Figure S3 Growth curve replicates at A) 26uC and B) 30uC. scc2-
4 growth curves were only run at 30uC and smc1-259 curves were
only assayed at 26uC. scc1-73 curves were run at both
temperatures because unlike the other two alleles, scc1-73 shows
a phenotype at both temperatures. In most cases if an interaction
with scc1-73 was present, it was more pronounced at 30uC. Some
interactions were tested with multiple alleles of the same gene. If
an interaction was identified the second allele was not always
assayed (denoted by black circles). Double mutants that were SL
according to random spore could not be analyzed by growth curve
analysis and are marked with ‘SL’. Gene A mutations refer to
cohesin alleles and gene B mutations refer to genes identified in the
SGA screens.
(TIF)
Figure S4 Strain fitness at 26uC ranked by interaction
magnitude. Each growth curve is assigned an individual estimate
of strain fitness reflecting the area under the curve (AUC) and
these are averaged for each strain. A neutral strain fitness estimate
is computed for each interaction and represents the theoretical
strain fitness of the double mutant under conditions of an additive,
non-synergistic genetic interaction. Synergistic interactions occur
when the experimental double mutant strain fitness deviates from
the neutral estimate. Interactions are ranked according to the
difference between the experimental and neutral strain fitness
estimates with stronger negative interactions occurring at the top
of the figure.
(TIF)
Figure S5 Strain fitness at 30uC ranked by interaction
magnitude. See Figure S4 legend for additional details.
(TIF)
Figure S6 Interaction T-statistics (26uC). T-statistics are ranked
according to magnitude. Dotted lines indicate a p-value cut off of
.05, and dashed lines indicate a Bonferroni corrected p-value of
.05.
(TIF)
Figure S7 Interaction T-statistics (30uC). T-statistics are ranked
according to magnitude. Dotted lines indicate a p-value cut off of
.05, and dashed lines indicate a Bonferroni corrected p-value of .05.
(TIF)
Figure S8 Replicative stress and increased apoptosis is seen in
him-1 mutants when treated with RNAi against genes that
mediate replication fork progression. A) Graph showing the
average number of apoptotic corpses per gonad arm. Predicted
bars represent the sum of the background levels of apoptotic
corpses in WT and him-1 and the effect of the RNAi on WT. B)
Representative images showing apoptotic corpses in untreated WT
and him-1 worms and worms treated with RAD61, CSM3, and
CTF8 RNAi. Error bars represent SEM.
(TIF)
Figure S9 Knockout of RAD51 does not rescue the lethality of
cohesion, fork mediator double mutants. RAD51 was replaced with
the resistance gene for hygromycin in double heterozygous smc1-
259 and fork mediator (CSM3, CTF4, CTF8, DCC1, RAD61)
mutants. The same was done for scc1-73, fork mediator double
mutants. Random spore was performed on all 10 triple mutants
and no rescue of lethality was seen in any cases. Random spore
results are shown for A) scc1-73, csm3D, rad51D and B) smc1-259,
ctf8D, rad51D triple heterozygotes.
(TIF)
Figure S10 HCT116 cells treated with siRNAs targeting various
cohesion genes are sensitive to the PARP inhibitor Benzamide.
HCT116 cells were transfected with the siRNA indicated and
exposed to 5 mM Benzamide for 3 days before fixing, staining
with Hoescht, and counting cell number using HC-DIM. Error
bars represent SEM.
(TIF)
Table S1 S. cerevisiae, C. elegans and human orthologs.
(DOCX)
Table S2 Double mutant interactions ranked by T-statistic at
26uC.
(DOCX)
Table S3 Double mutant interactions ranked T-statistic at 30uC.
(DOCX)
Table S4 Summary of interactions identified by Growth Curve
Analysis.
(DOCX)
Table S5 Reported CIN Phenotypes of cohesin interacting
genes.
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Table S6 SGA scores for the major genes involved in
homologous recombination.
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Table S7 Diploid S. cerevisiae strains used in this study.
(DOCX)
Table S8 Haploid S. cerevisiae strains used in this study.
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Table S9 C. elegans strains.
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